Non-CME/CE
Obesity Medicine
The prevalence of Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) is increasing. Recognizing patients at risk for MASH is important for early screening and diagnosis.
Boehringer Ingelheim Pharmaceuticals, Inc.